Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Science"
DOI: 10.1111/cas.13430
Abstract: Tyrosine kinase inhibitors (TKI) improve the prognosis of patients with chronic myelogenous leukemia (CML) by inducing substantial deep molecular responses (DMR); some patients have successfully discontinued TKI therapy after maintaining DMR for ≥1 year. In… read more here.
Keywords: consolidation; dasatinib consolidation; deep molecular; natural killer ... See more keywords